A compound of formula I or II: in which: L is selected from -NHC(O)- and -C(O)NH-; Y 1 is selected from N and CH; R 1 is selected from H, halo, isopropyl, methyl-sulfonyl, OR 6 , NR 5 R 6 , methoxy-ethoxy, 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 2-oxo-1,2-dihydropyridin-4-yl, tetrahydro-2H-pyranyl, 4-oxopyridin-1 -yl, pyrazolyl, pyridazinyl and azetidinyl; wherein said azetidinyl, pyrazolyl or 2-oxo-1,2-dihydropyridin-4-yl is unsubstituted or substituted with 1 to 3 groups independently selected from methyl and hydroxy; R 2 is selected from H and methyl; R 3 is selected from H, methyl and amino; R 4 is selected from: wherein indicates the point of attachment with L; R 5 is selected from H and methyl; R 6 is selected from H and methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, hydroxy-ethyl, methoxy-ethyl, tetrahydro-2H-pyranyl, pyridinyl, tetrahydrofuranyl and oxetanyl; or R 5 and R 6 , together with the nitrogen to which R 5 and R 6 are attached form a group selected from morpholino, 2-oxopyridin-1 -yl, 1,1-dioxidothiomorpholino, piperazinyl, pyrrolidinyl, imidazolyl and pyrazolyl; wherein said morpholino, pyrazolyl or imidazolyl can be unsubstituted or substituted with 1 to 2 methyl groups; R 7 is selected from H, methyl, -CF 3 , -C(CH 3 ) 2 CN, -C(CH 3 ) 2 OH, -C(CH 3 ) 2 F, -CF 2 CH 3 , - CF 2 H, isopropyl, cyclopropyl and methyl-sulfonyl; wherein said cyclopropyl is unsubstituted or substituted with cyano; R 8 is selected from H, methyl, ethyl, isopropyl, -C(CH 3 ) 2 OH and -C(CH 3 ) 2 NH 2 ; R 9 is selected from H and ethyl; or the compound is N-(3-(2-chloro-5-cyanopyridin-3-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide or a pharmaceutically acceptable salt thereof. L is selected from -NHC(O)- and -C(O)NH-; Y 1 is selected from N and CH; R 1 is selected from H, halo, isopropyl, methyl-sulfonyl, OR 6 , NR 5 R 6 , methoxy-ethoxy, 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 2-oxo-1,2-dihydropyridin-4-yl, tetrahydro-2H-pyranyl, 4-oxopyridin-1 -yl, pyrazolyl, pyridazinyl and azetidinyl; wherein said azetidinyl, pyrazolyl or 2-oxo-1,2-dihydropyridin-4-yl is unsubstituted or substituted with 1 to 3 groups independently selected from methyl and hydroxy; R 2 is selected from H and methyl; R 3 is selected from H, methyl and amino; R 4 is selected from: wherein indicates the point of attachment with L; R 5 is selected from H and methyl; R 6 is selected from H and methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, hydroxy-ethyl, methoxy-ethyl, tetrahydro-2H-pyranyl, pyridinyl, tetrahydrofuranyl and oxetanyl; or R 5 and R 6 , together with the nitrogen to which R 5 and R 6 are attached form a group selected from morpholino, 2-oxopyridin-1 -yl, 1,1-dioxidothiomorpholino, piperazinyl, pyrrolidinyl, imidazolyl and pyrazolyl; wherein said morpholino, pyrazolyl or imidazolyl can be unsubstituted or substituted with 1 to 2 methyl groups; R 7 is selected from H, methyl, -CF 3 , -C(CH 3 ) 2 CN, -C(CH 3 ) 2 OH, -C(CH 3 ) 2 F, -CF 2 CH 3 , - CF 2 H, isopropyl, cyclopropyl and methyl-sulfonyl; wherein said cyclopropyl is unsubstituted or substituted with cyano; R 8 is selected from H, methyl, ethyl, isopropyl, -C(CH 3 ) 2 OH and -C(CH 3 ) 2 NH 2 ; R 9 is selected from H and ethyl; or the compound is N-(3-(2-chloro-5-cyanopyridin-3-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide or a pharmaceutically acceptable salt thereof. <EOS>